Eiger BioPharmaceuticals, Inc.
EIGR
EIGR was delisted on the 10th of April, 2024.
41 hedge funds and large institutions have $11.4M invested in Eiger BioPharmaceuticals, Inc. in 2015 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 10 closing their positions.
79% more capital invested
Capital invested by funds: $6.36M → $11.4M (+$5.05M)
0% more funds holding
Funds holding: 41 → 41 (0)
0% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 10
36% less call options, than puts
Call options by funds: $7K | Put options by funds: $11K
40% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
+$1.84M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$331K |
| 3 |
Millennium Management
New York
|
+$88.3K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$55.4K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
+$36.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$861K |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$430K |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$257K |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$57.7K |
| 5 |
AL
Airain Ltd
St. Peter Port,
Guernsey
|
-$38K |
EIGR Hedge Fund Activity: Q4 2015 in Review
41 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q4 2015, worth a combined $11.4M — up 79% from $6.36M a quarter earlier.
Fund positioning in EIGR was balanced in Q4 2015: 10 funds opened new positions, 10 closed out, 6 added to existing stakes and 10 trimmed.
The largest buyer was Lombard Odier Asset Management (USA), opening a new position worth an estimated $1.84M. The largest seller was Acuta Capital Partners, exiting entirely with an estimated $861K sold.
- 41 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q4 2015, unchanged from Q3 2015.
- Funds reported $11.4M of Eiger BioPharmaceuticals, Inc. stock for Q4 2015, up 79% quarter-over-quarter.
- 10 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q4 2015 and 10 closed out, a net change of 0 holders.
- The largest Eiger BioPharmaceuticals, Inc. buyer in Q4 2015 was Lombard Odier Asset Management (USA), an estimated $1.84M added.
- The largest Eiger BioPharmaceuticals, Inc. seller in Q4 2015 was Acuta Capital Partners, an estimated $861K sold.
Based on aggregated 13F filings for Q4 2015.